Related Experiment Video
Updated: Aug 18, 2025
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
17.8K
Biosimilars for immune-mediated inflammatory diseases: a managed care perspective
Colby Evans1, Allan Gibofsky, Vibeke Strand
1National Psoriasis Foundation, Austin, TX.
The American Journal of Managed Care
|December 9, 2022
Summary
Biosimilars offer significant healthcare cost savings without compromising safety or efficacy. However, their adoption in the U.S. is slow due to systemic barriers within the healthcare system.
Area of Science:
- Health Economics
- Pharmaceutical Policy
- Pharmacology
Background:
- Biosimilars present an opportunity for considerable healthcare cost reduction.
- The United States has experienced slower biosimilar adoption compared to expectations.
- Existing literature addresses patient and provider barriers, necessitating further examination of systemic issues.
Purpose of the Study:
- To analyze biosimilar agents from a managed care viewpoint.
- To identify and discuss barriers to biosimilar adoption within the U.S. healthcare system.
- To understand the reasons for delayed U.S. uptake of biosimilars.
Main Methods:
- Review of current U.S. healthcare system structures.
- Analysis of managed care perspectives on biosimilars.
- Identification of systemic barriers impacting biosimilar utilization.
Main Results:
- Systemic factors within the U.S. healthcare infrastructure contribute to slow biosimilar adoption.
- Managed care perspectives reveal specific challenges hindering biosimilar integration.
- Barriers extend beyond patient and provider issues, encompassing broader system-level impediments.
Conclusions:
- Addressing systemic barriers is crucial for increasing biosimilar adoption in the U.S.
- Managed care strategies need to be developed to facilitate biosimilar use.
- Overcoming these hurdles will unlock the cost-saving potential of biosimilars.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
169
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
210
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
210
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
244
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
244
01:17Drugs Used in Lower Respiratory Disorders: Overview
544
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
544
01:28Inflammatory Response
4.5K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
4.5K
01:16Bioequivalence: Overview
1.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.2K